Melphalan

General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
12
Half-Life (Normalesrd) Hours
1.1-1.4/4-6
Plasma Protein Binding %
90
Volume Of Distribution L/Kg
0.6-0.75
Dose For Normal Renal Function
6.0 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Alberts DS, Chang SY, Chen HS, Moon TE, Evans TL, Furner RL, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther. 1979; 26: 73-80. [PMID: 445964] / Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res. 1994; 14: 2379-82. [PMID: 7825976]